<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30987270</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>Apr</Month><Day>04</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Essential Role of Visfatin in Lipopolysaccharide and Colon Ascendens Stent Peritonitis-Induced Acute Lung Injury.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1678</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20071678</ELocationID><Abstract><AbstractText>Acute lung injury (ALI) is a life-threatening syndrome characterized by acute and severe hypoxemic respiratory failure. Visfatin, which is known as an obesity-related cytokine with pro-inflammatory activities, plays a role in regulation of inflammatory cytokines. The mechanisms of ALI remain unclear in critically ill patients. Survival in ALI patients appear to be influenced by the stress generated by mechanical ventilation and by ALI-associated factors that initiate the inflammatory response. The objective for this study was to understand the mechanisms of how visfatin regulates inflammatory cytokines and promotes ALI. The expression of visfatin was evaluated in ALI patients and mouse sepsis models. Moreover, the underlying mechanisms were investigated using human bronchial epithelial cell lines, BEAS-2B and NL-20. An increase of serum visfatin was discovered in ALI patients compared to normal controls. Results from hematoxylin and eosin (H&amp;amp;E) and immunohistochemistry staining also showed that visfatin protein was upregulated in mouse sepsis models. Moreover, lipopolysaccharide (LPS) induced visfatin expression, activated the STAT3/NF&#x3ba;B pathway, and increased the expression of pro-inflammatory cytokines, including IL1-&#x3b2;, IL-6, and TNF-&#x3b1; in human bronchial epithelial cell lines NL-20 and BEAS-2B. Co-treatment of visfatin inhibitor FK866 reversed the activation of the STAT3/NF&#x3ba;B pathway and the increase of pro-inflammatory cytokines induced by LPS. Our study provides new evidence for the involvement of visfatin and down-stream events in acute lung injury. Further studies are required to confirm whether the anti-visfatin approaches can improve ALI patient survival by alleviating the pro-inflammatory process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yi-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Translational Research Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. yichen83@kmu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. yichen83@kmu.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chun-Yu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>School of Medicine, Graduate Institute of Medicine, Sepsis Research Center, Center of Dengue Fever Control and Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan. infectionman@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. infectionman@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yen-Hsu</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>School of Medicine, Graduate Institute of Medicine, Sepsis Research Center, Center of Dengue Fever Control and Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan. d810070@kmu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 801, Taiwan. d810070@kmu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Science and Technology, College of Biological Science and Technology, National Chiao Tung University, Hsinchu 300, Taiwan. d810070@kmu.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Wen-Chin</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Translational Research Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. wlkb3065@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. wlkb3065@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yen-Yun</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. winnie30304@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Chin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. chinhsu@kmu.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Stephen Chu-Sung</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Medical University, Kaohsiung 807, Taiwan. stephenhu30@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yu-Han</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Translational Research Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. winnie30304@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shyng-Shiou F</ForeName><Initials>SF</Initials><Identifier Source="ORCID">0000-0002-4753-788X</Identifier><AffiliationInfo><Affiliation>Translational Research Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. yuanssf@ms33.hinet.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Science and Technology, College of Biological Science and Technology, National Chiao Tung University, Hsinchu 300, Taiwan. yuanssf@ms33.hinet.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Research and Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. yuanssf@ms33.hinet.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. yuanssf@ms33.hinet.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Intelligent Drug Systems and Smart Bio-devices (IDS2B), National Chiao Tung University, Hsinchu 300, Taiwan. yuanssf@ms33.hinet.net.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000178">Acrylamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C480543">N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.2.12</RegistryNumber><NameOfSubstance UI="D054409">Nicotinamide Phosphoribosyltransferase</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000178" MajorTopicYN="N">Acrylamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055371" MajorTopicYN="N">Acute Lung Injury</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054409" MajorTopicYN="N">Nicotinamide Phosphoribosyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010538" MajorTopicYN="N">Peritonitis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015607" MajorTopicYN="N">Stents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FK866</Keyword><Keyword MajorTopicYN="N">acute lung injury</Keyword><Keyword MajorTopicYN="N">visfatin</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30987270</ArticleId><ArticleId IdType="pmc">PMC6480124</ArticleId><ArticleId IdType="doi">10.3390/ijms20071678</ArticleId><ArticleId IdType="pii">ijms20071678</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matthay M.A., Zimmerman G.A. Acute lung injury and the acute respiratory distress syndrome: Four decades of inquiry into pathogenesis and rational management. Am. J. Respir. Cell Mol. Biol. 2005;33:319&#x2013;327. doi: 10.1165/rcmb.F305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.F305</ArticleId><ArticleId IdType="pmc">PMC2715340</ArticleId><ArticleId IdType="pubmed">16172252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortelliti M.P., Manning H.L. Acute respiratory distress syndrome. Am. Fam. Phys. 2002;65:1823&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pubmed">12018805</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Zimmerman G.A., Esmon C., Bhattacharya J., Coller B., Doerschuk C.M., Floros J., Gimbrone M.A., Jr., Hoffman E., Hubmayr R.D., et al. Future research directions in acute lung injury: Summary of a National Heart, Lung, and Blood Institute working group. Am. J. Respir. Crit. Care Med. 2003;167:1027&#x2013;1035. doi: 10.1164/rccm.200208-966WS.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200208-966WS</ArticleId><ArticleId IdType="pubmed">12663342</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenfeld G.D., Caldwell E., Peabody E., Weaver J., Martin D.P., Neff M., Stern E.J., Hudson L.D. Incidence and outcomes of acute lung injury. New Engl. J. Med. 2005;353:1685&#x2013;1693. doi: 10.1056/NEJMoa050333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa050333</ArticleId><ArticleId IdType="pubmed">16236739</ArticleId></ArticleIdList></Reference><Reference><Citation>Goss C.H., Brower R.G., Hudson L.D., Rubenfeld G.D., Network A. Incidence of acute lung injury in the United States. Crit. Care Med. 2003;31:1607&#x2013;1611. doi: 10.1097/01.CCM.0000063475.65751.1D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000063475.65751.1D</ArticleId><ArticleId IdType="pubmed">12794394</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasudevan A., Lodha R., Kabra S.K. Acute lung injury and acute respiratory distress syndrome. Indian J. Pediatrics. 2004;71:743&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">15345878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware L.B., Matthay M.A. The acute respiratory distress syndrome. New Engl. J. Med. 2000;342:1334&#x2013;1349. doi: 10.1056/NEJM200005043421806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200005043421806</ArticleId><ArticleId IdType="pubmed">10793167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware L.B. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin. Respir. Crit. Care Med. 2006;27:337&#x2013;349. doi: 10.1055/s-2006-948288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2006-948288</ArticleId><ArticleId IdType="pubmed">16909368</ArticleId></ArticleIdList></Reference><Reference><Citation>Luh S.P., Chiang C.H. Acute lung injury/acute respiratory distress syndrome (ALI/ARDS): The mechanism, present strategies and future perspectives of therapies. J. Zhejiang Univ. Sci. B. 2007;8:60&#x2013;69. doi: 10.1631/jzus.2007.B0060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1631/jzus.2007.B0060</ArticleId><ArticleId IdType="pmc">PMC1764923</ArticleId><ArticleId IdType="pubmed">17173364</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson E.R., Matthay M.A. Acute lung injury: Epidemiology, pathogenesis, and treatment. J. Aerosol Med. Pulm. Drug Deliv. 2010;23:243&#x2013;252. doi: 10.1089/jamp.2009.0775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jamp.2009.0775</ArticleId><ArticleId IdType="pmc">PMC3133560</ArticleId><ArticleId IdType="pubmed">20073554</ArticleId></ArticleIdList></Reference><Reference><Citation>Calfee C.S., Matthay M.A. Nonventilatory treatments for acute lung injury and ARDS. Chest. 2007;131:913&#x2013;920. doi: 10.1378/chest.06-1743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.06-1743</ArticleId><ArticleId IdType="pmc">PMC2789489</ArticleId><ArticleId IdType="pubmed">17356114</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz J.V., Brower R., Calfee C.S., Matthay M.A. Therapeutic strategies for severe acute lung injury. Crit. Care Med. 2010;38:1644&#x2013;1650. doi: 10.1097/CCM.0b013e3181e795ee.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181e795ee</ArticleId><ArticleId IdType="pmc">PMC4526259</ArticleId><ArticleId IdType="pubmed">20562704</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrera G., Landoni V., Martire-Greco D., Chiarella P., Meiss R., Gomez S.A., Alves-Rosa F., Rearte B., Isturiz M., Palermo M.S., et al. Model of polymicrobial peritonitis that induces the proinflammatory and immunosuppressive phases of sepsis. Infect. Immun. 2011;79:1280&#x2013;1288. doi: 10.1128/IAI.01127-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.01127-10</ArticleId><ArticleId IdType="pmc">PMC3067524</ArticleId><ArticleId IdType="pubmed">21173307</ArticleId></ArticleIdList></Reference><Reference><Citation>Feterowski C., Emmanuilidis K., Miethke T., Gerauer K., Rump M., Ulm K., Holzmann B., Weighardt H. Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology. 2003;109:426&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1782987</ArticleId><ArticleId IdType="pubmed">12807489</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons P.E. Mediators and mechanisms of acute lung injury. Clin. Chest Med. 2000;21:467&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">11019720</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia M., Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J. Pathol. 2004;202:145&#x2013;156. doi: 10.1002/path.1491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1491</ArticleId><ArticleId IdType="pubmed">14743496</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold S., Gabrielli N.M., Vadasz I. Novel concepts of acute lung injury and alveolar-capillary barrier dysfunction. Am. J. Physiology. Lung Cell. Mol. Physiol. 2013;305:L665&#x2013;L681. doi: 10.1152/ajplung.00232.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00232.2013</ArticleId><ArticleId IdType="pubmed">24039257</ArticleId></ArticleIdList></Reference><Reference><Citation>Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 1994;14:1431&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC358498</ArticleId><ArticleId IdType="pubmed">8289818</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Liu P., Cepeda J., Fang D., Easley R.B., Simon B.A., Zhang L.Q., Ye S.Q. Augmentation of Pulmonary Epithelial Cell IL-8 Expression and Permeability by Pre-B-cell Colony Enhancing Factor. J. Inflamm. 2008;5:15. doi: 10.1186/1476-9255-5-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-9255-5-15</ArticleId><ArticleId IdType="pmc">PMC2559829</ArticleId><ArticleId IdType="pubmed">18808711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitani T., Okuno S., Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett. 2003;544:74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">12782293</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia S.H., Li Y., Parodo J., Kapus A., Fan L., Rotstein O.D., Marshall J.C. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J. Clin. Investig. 2004;113:1318&#x2013;1327. doi: 10.1172/JCI19930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI19930</ArticleId><ArticleId IdType="pmc">PMC398427</ArticleId><ArticleId IdType="pubmed">15124023</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z., Lei H., Zhang Z. Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. Cytokine Growth Factor Rev. 2013;24:433&#x2013;442. doi: 10.1016/j.cytogfr.2013.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2013.05.006</ArticleId><ArticleId IdType="pmc">PMC3791181</ArticleId><ArticleId IdType="pubmed">23787158</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonoli S.S., Shivprasad S., Prasad C.V., Patil A.B., Desai P.B., Somannavar M.S. Visfatin&#x2014;A review. Eur. Rev. Med Pharmacol. Sci. 2011;15:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">21381495</ArticleId></ArticleIdList></Reference><Reference><Citation>Revollo J.R., Grimm A.A., Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 2004;279:50754&#x2013;50763. doi: 10.1074/jbc.M408388200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M408388200</ArticleId><ArticleId IdType="pubmed">15381699</ArticleId></ArticleIdList></Reference><Reference><Citation>Rongvaux A., Shea R.J., Mulks M.H., Gigot D., Urbain J., Leo O., Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 2002;32:3225&#x2013;3234. doi: 10.1002/1521-4141(200211)32:113.0.CO;2-L.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1521-4141(200211)32:113.0.CO;2-L</ArticleId><ArticleId IdType="pubmed">12555668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ognjanovic S., Bryant-Greenwood G.D. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am. J. Obstet. Gynecol. 2002;187:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">12389004</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426&#x2013;430. doi: 10.1126/science.1097243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1097243</ArticleId><ArticleId IdType="pubmed">15604363</ArticleId></ArticleIdList></Reference><Reference><Citation>Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007;178:1748&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pubmed">17237424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S.Q., Zhang L.Q., Adyshev D., Usatyuk P.V., Garcia A.N., Lavoie T.L., Verin A.D., Natarajan V., Garcia J.G. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc. Res. 2005;70:142&#x2013;151. doi: 10.1016/j.mvr.2005.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2005.08.003</ArticleId><ArticleId IdType="pubmed">16188281</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowell M.A., Richards P.J., Fielding C.A., Ognjanovic S., Topley N., Williams A.S., Bryant-Greenwood G., Jones S.A. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: Implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2006;54:2084&#x2013;2095. doi: 10.1002/art.21942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21942</ArticleId><ArticleId IdType="pubmed">16802343</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahl T.B., Yndestad A., Skjelland M., Oie E., Dahl A., Michelsen A., Damas J.K., Tunheim S.H., Ueland T., Smith C., et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation. 2007;115:972&#x2013;980. doi: 10.1161/CIRCULATIONAHA.106.665893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.665893</ArticleId><ArticleId IdType="pubmed">17283255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S.B., Huang Y., Moreno-Vinasco L., Sammani S., Moitra J., Barnard J.W., Ma S.F., Mirzapoiazova T., Evenoski C., Reeves R.R., et al. Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury. Am. J. Respir. Crit. Care Med. 2008;178:605&#x2013;617. doi: 10.1164/rccm.200712-1822OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200712-1822OC</ArticleId><ArticleId IdType="pmc">PMC2542434</ArticleId><ArticleId IdType="pubmed">18658108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S.Q., Simon B.A., Maloney J.P., Zambelli-Weiner A., Gao L., Grant A., Easley R.B., McVerry B.J., Tuder R.M., Standiford T., et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am. J. Respir. Crit. Care Med. 2005;171:361&#x2013;370. doi: 10.1164/rccm.200404-563OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200404-563OC</ArticleId><ArticleId IdType="pubmed">15579727</ArticleId></ArticleIdList></Reference><Reference><Citation>Manicone A.M. Role of the pulmonary epithelium and inflammatory signals in acute lung injury. Expert Rev. Clin. Immunol. 2009;5:63&#x2013;75. doi: 10.1586/177666X.5.1.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/177666X.5.1.63</ArticleId><ArticleId IdType="pmc">PMC2745180</ArticleId><ArticleId IdType="pubmed">19885383</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M.H., Tsai C.H., Huang Y.L., Fong Y.C., Tang C.H. Visfatin Promotes IL-6 and TNF-alpha Production in Human Synovial Fibroblasts by Repressing miR-199a-5p through ERK, p38 and JNK Signaling Pathways. Int. J. Mol. Sci. 2018;19:190. doi: 10.3390/ijms19010190.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19010190</ArticleId><ArticleId IdType="pmc">PMC5796139</ArticleId><ArticleId IdType="pubmed">29316707</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig M.K., Bac V.H., Pavlovic D., Maier S., Grundling M., Grisk O., Wendt M., Heidecke C.D., Lehmann C. Colon ascendens stent peritonitis&#x2014;A model of sepsis adopted to the rat: Physiological, microcirculatory and laboratory changes. Shock. 2007;28:59&#x2013;64. doi: 10.1097/SHK.0b013e31802e454f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e31802e454f</ArticleId><ArticleId IdType="pubmed">17483746</ArticleId></ArticleIdList></Reference><Reference><Citation>Traeger T., Koerner P., Kessler W., Cziupka K., Diedrich S., Busemann A., Heidecke C.D., Maier S. Colon ascendens stent peritonitis (CASP)&#x2014;A standardized model for polymicrobial abdominal sepsis. J. Vis. Exp. JoVE. 2010 doi: 10.3791/2299.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2299</ArticleId><ArticleId IdType="pmc">PMC3159662</ArticleId><ArticleId IdType="pubmed">21206468</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda A., Yang W.L., Jacob A., Aziz M., Matsuo S., Matsutani T., Uchida E., Wang P. FK866, a visfatin inhibitor, protects against acute lung injury after intestinal ischemia-reperfusion in mice via NF-kappaB pathway. Ann. Surg. 2014;259:1007&#x2013;1017. doi: 10.1097/SLA.0000000000000329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000000329</ArticleId><ArticleId IdType="pubmed">24169192</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster S., Penke M., Gorski T., Gebhardt R., Weiss T.S., Kiess W., Garten A. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells. Biochem. Biophys. Res. Commun. 2015;458:334&#x2013;340. doi: 10.1016/j.bbrc.2015.01.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2015.01.111</ArticleId><ArticleId IdType="pubmed">25656579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.Y., Bae Y.H., Bae M.K., Kim S.R., Park H.J., Wee H.J., Bae S.K. Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim. Biophys. Acta. 2009;1793:1759&#x2013;1767. doi: 10.1016/j.bbamcr.2009.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2009.09.006</ArticleId><ArticleId IdType="pubmed">19751774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi T.Q., Che X.M. Nampt/PBEF/visfatin and cancer. Cancer Biol. Ther. 2010;10:119&#x2013;125. doi: 10.4161/cbt.10.2.12581.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cbt.10.2.12581</ArticleId><ArticleId IdType="pubmed">20647743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung A.C., Lo S., Hou M.F., Lee Y.C., Tsai C.H., Chen Y.Y., Liu W., Su Y.H., Lo Y.H., Wang C.H., et al. Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2016;22:4478&#x2013;4490. doi: 10.1158/1078-0432.CCR-15-2704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-2704</ArticleId><ArticleId IdType="pubmed">27036136</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Zhang Y., Dorweiler B., Cui D., Wang T., Woo C.W., Brunkan C.S., Wolberger C., Imai S., Tabas I. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J. Biol. Chem. 2008;283:34833&#x2013;34843. doi: 10.1074/jbc.M805866200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M805866200</ArticleId><ArticleId IdType="pmc">PMC2596403</ArticleId><ArticleId IdType="pubmed">18945671</ArticleId></ArticleIdList></Reference><Reference><Citation>Oita R.C., Ferdinando D., Wilson S., Bunce C., Mazzatti D.J. Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFkB-dependent manner. Pflug. Arch. Eur. J. Physiol. 2010;459:619&#x2013;630. doi: 10.1007/s00424-009-0752-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-009-0752-1</ArticleId><ArticleId IdType="pubmed">19898975</ArticleId></ArticleIdList></Reference><Reference><Citation>Camp S.M., Ceco E., Evenoski C.L., Danilov S.M., Zhou T., Chiang E.T., Moreno-Vinasco L., Mapes B., Zhao J., Gursoy G., et al. Unique Toll-Like Receptor 4 Activation by NAMPT/PBEF Induces NFkappaB Signaling and Inflammatory Lung Injury. Sci. Rep. 2015;5:13135. doi: 10.1038/srep13135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep13135</ArticleId><ArticleId IdType="pmc">PMC4536637</ArticleId><ArticleId IdType="pubmed">26272519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.W., Jr., Sevryugina Y.V., Khan A., Ye S.Q. Carboranes increase the potency of small molecule inhibitors of nicotinamide phosphoribosyltranferase. J. Med. Chem. 2012;55:7290&#x2013;7294. doi: 10.1021/jm300740t.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm300740t</ArticleId><ArticleId IdType="pubmed">22889195</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P., Lee M.W., Jr., Sadrerafi K., Heruth D.P., Zhang L.Q., Maulik D., Ye S.Q. MC-PPEA as a new and more potent inhibitor of CLP-induced sepsis and pulmonary inflammation than FK866. Drug Des. Dev. Ther. 2017;11:629&#x2013;641. doi: 10.2147/DDDT.S125349.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S125349</ArticleId><ArticleId IdType="pmc">PMC5344436</ArticleId><ArticleId IdType="pubmed">28424540</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour C.W., Liu V.X., Iwashyna T.J., Brunkhorst F.M., Rea T.D., Scherag A., Rubenfeld G., Kahn J.M., Shankar-Hari M., Singer M., et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA. 2016;315:762&#x2013;774. doi: 10.1001/jama.2016.0288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0288</ArticleId><ArticleId IdType="pmc">PMC5433435</ArticleId><ArticleId IdType="pubmed">26903335</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenfeld G.D., Herridge M.S. Epidemiology and outcomes of acute lung injury. Chest. 2007;131:554&#x2013;562. doi: 10.1378/chest.06-1976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.06-1976</ArticleId><ArticleId IdType="pubmed">17296661</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Tian Y., Yang J., Li J., Tang H., Wang Y. Colon Ascendens Stent Peritonitis (CASP) Induces Excessive Inflammation and Systemic Metabolic Dysfunction in a Septic Rat Model. J. Proteome Res. 2018;17:680&#x2013;688. doi: 10.1021/acs.jproteome.7b00730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.7b00730</ArticleId><ArticleId IdType="pubmed">29205045</ArticleId></ArticleIdList></Reference><Reference><Citation>Debaugnies F., Mahadeb B., Ferster A., Meuleman N., Rozen L., Demulder A., Corazza F. Performances of the H-Score for Diagnosis of Hemophagocytic Lymphohistiocytosis in Adult and Pediatric Patients. Am. J. Clin. Pathol. 2016;145:862&#x2013;870. doi: 10.1093/ajcp/aqw076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqw076</ArticleId><ArticleId IdType="pubmed">27298397</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>